A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Dec 1, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
• • Patients currently on IOP reducing therapy: IOP greater than or equal to 25mmHg (Ltwo IOP determinations at pre-study separated by at least one hour) OR Patients without IOP reducing therapy: IOP greater than or equal to 30mmHg (two IOP determinations at pre-study separated by at least one hour).
• Exclusion Criteria:
• • History of acute angle closure or closed/barely open anterior chamber angle.
• • Current use of contact lenses.
• • Ocular surgery or argon laser trabeculoplasty (ALT) within three months prior to pre-study visit.
• • Ocular inflammation/infection occurring within three months prior to pre-study visit.
• • Hypersensitivity to benzalkonium chloride or to any other component of the study drug solutions.
• • Other abnormal ocular condition or symptom preventing the patient from entering the study, according to the investigator's judgement.
• • Patients with conditions in which treatment with B-blocking agents are contraindicated: cardiac failure, sinus bradycardia, second and third degree atrio-ventricular block.
• • Patients with conditions in which treatment with B-blocking agents are contraindicated: bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease.
• • Inability to adhere to treatment/visit plan.
• • Have participated in any other clinical study within one month prior to pre-study visit.